RxDoctor Payments Data

George Rodgers, MD

Hematology · Salt Lake City, UTNPI 1578512190

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $82,224 of the $133,182 with a category attached, or 61.7%. It is spread thinly across 18 manufacturers, the largest accounting for just 22.1%. Reporting peaked in 2022 at $33,658 and has fallen 82.4% since, to $5,926 in 2025.

$133,182in general payments, 2019–2025

Across 99 payments — averaging $1345.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacosmos Therapeutics Inc.$29K
  • Sanofi$21K
  • AstraZeneca$20K
  • Grifols, S.A.$17K
  • Dova Pharmaceuticals$16K
  • Genentech USA, Inc.$7K
  • plus $24K from 12 others
$86,887in research payments, 2019–2025

Across 20 payments — averaging $4344.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sobi, Inc$57K
  • Pfizer$10K
  • Bayer$9K
  • Rigel Pharmaceuticals, Inc.$6K
  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • Janssen Research & Development, LLC$2K

What the payments were for

  • Consulting fees$82,22462%
  • Speaking & faculty fees$29,74322%
  • Travel & lodging$18,11214%
  • Food & beverage$3,1042%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Utahto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$33,991
Medicare patients
175
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$34,472
XareltoRivaroxaban20$29,274
AranespDarbepoetin Alfa In Polysorbat11$11,467
Enoxaparin Sodium23$6,751
Cyclosporine ModifiedCyclosporine, Modified24$1,339
Tranexamic Acid31$1,331
Hydroxyurea16$381
Dexamethasone13$164
Celecoxib11$75

Paid to pharmacies, not to this prescriber.

Other hematology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →